中晚期原发性非小细胞肺癌的前瞻性研究.docVIP

中晚期原发性非小细胞肺癌的前瞻性研究 中晚期期原发性非小细胞肺癌的前瞻瞻性研究1年治疗后1年生存存率中位生存率 博生癌宁组组3022例13例538443235天 对照组32221例5例238192天 表3博生癌宁治疗后各种癌症症分布及生存情况 生存期 癌种例数1年1－3年3－55年10－16年 例数例数数例数例数 食管癌3086679 胃癌352101449 肺癌3049116 肝癌208084 肠癌811511 鼻咽癌1592331 宫颈癌102422 膀胱癌102602 其他癌癌症2851094 治疗后后病灶变化,按照H抗肿瘤药药物疗效通用标准评定。以患患者入院治疗前后胸片进行对对照比较,以\”部分缓解\\”,\”稳定\”,\”恶恶化\”进行疗效评定,见表表4。提示博生癌宁组治疗后后稳定瘤灶的疗效明显优于对对照组。 表4博生癌宁与对对照组治疗后病灶变化 组别别例数部分缓解稳定恶化稳定定率值中位稳定期 博生癌宁宁t;;0056月 对照组300019116333005 对照组307367±199316565±5457113656lt;0001 治疗前后免疫,生化指标的的变化为探讨中晚期肺癌患者者的免疫状态,博生癌宁对机机体免疫状态的影响,以及博博生癌宁治疗中晚期肺癌的作作用机理,我们以巨噬细胞吞吞噬活性测定,K细胞活力测测定等作为检测指标,对随机机分为两组的病例,进行治疗疗前后检测,实验结果如下:: 1、巨噬细胞吞噬活性试试验:用皮肤发泡取吞噬细胞胞，吞噬细胞法测定肺癌患者者的吞噬功能。博生癌宁组患患者治疗后吞噬功能明显高于于治疗前,对照组治疗后略低低于治疗前,但无统计学意义义,见表6。 2、K细胞活活力测定:从表7可见,博生生癌宁组患者治疗后K细胞活活力明显高于对照组,显示了了博生癌宁治疗后可明显提高高中晚期肺癌患者的K细胞的的杀伤作用,并随服药时间适适当延长而活性相应提高。 表6治疗前后巨噬细胞吞噬噬活性变化 组别项目例数治治疗前治疗后t值p值 X±±SX±S 吞噬率3041110±3358153333±257324560 education on Party membersadvancement activities and enhance awareness of the Communist Youth League education achievements, and vigorously promote the construction of civilization advanced units, units and staff home building activities, balanced, focused, pragmatic, innovation, high standard, high quality, high level, high efficiency to complete various tasks throughout the year.First, pay close attention to research information, efforts to improve decision-making servicesIn accordance with the information reflect the information, promote the work of information leading work requirements, adhere to grasp the team construction, mechanism construction and quantitative assessment, give full play to the assistant role of leadership, actively promote the innovation of research information development, and vigorously promote the research work of information to mention upgrading, efforts to improve the ability and level of decision-making.(a) adhere to the decision in the first place. To make the decision service as the focus of the work, participate in the point, and in the key